Literature DB >> 23644232

Mammalian target of rapamycin (mTOR) pathways in neurological diseases.

Michael Wong1.   

Abstract

The mammalian target of rapamycin (mTOR) pathway is an essential cellular signaling pathway involved in a number of important physiological functions, including cell growth, proliferation, metabolism, protein synthesis, and autophagy. Dysregulation of the mTOR pathway has been implicated in the pathophysiology of a number of neurological diseases. Hyperactivation of the mTOR pathway, leading to increased cell growth and proliferation, has been most convincingly shown to stimulate tumor growth in the brain and other organs in the genetic disorder, tuberous sclerosis complex (TSC). In addition, mTOR may also play a role in promoting epileptogenesis or maintaining seizures in TSC, as well as in acquired epilepsies following brain injury. Finally, the mTOR pathway may also be involved in the pathogenesis of cognitive dysfunction and other neurological deficits in developmental disorders and neurodegenerative diseases. mTOR inhibitors, such as rapamycin and its analogs, may represent novel, rational therapies for a variety of neurological disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23644232      PMCID: PMC3880546          DOI: 10.4103/2319-4170.110365

Source DB:  PubMed          Journal:  Biomed J        ISSN: 2319-4170            Impact factor:   4.910


  90 in total

1.  Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.

Authors:  Anna K Haemel; Amy L O'Brian; Joyce M Teng
Journal:  Arch Dermatol       Date:  2010-07

2.  Association between AKT/mTOR signalling pathway and malignancy grade of human gliomas.

Authors:  Xue-Yuan Li; Lian-Qun Zhang; Xue-Guang Zhang; Xin Li; Yu-Bo Ren; Xiang-Yu Ma; Xin-Gang Li; Le-Xin Wang
Journal:  J Neurooncol       Date:  2010-09-29       Impact factor: 4.130

3.  Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

Authors:  Darcy A Krueger; Marguerite M Care; Katherine Holland; Karen Agricola; Cynthia Tudor; Prajakta Mangeshkar; Kimberly A Wilson; Anna Byars; Tarek Sahmoud; David Neal Franz
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

4.  STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice.

Authors:  Ksenia A Orlova; Whitney E Parker; Gregory G Heuer; Victoria Tsai; Jason Yoon; Marianna Baybis; Robert S Fenning; Kevin Strauss; Peter B Crino
Journal:  J Clin Invest       Date:  2010-04-26       Impact factor: 14.808

5.  An increase in basal BDNF provokes hyperactivation of the Akt-mammalian target of rapamycin pathway and deregulation of local dendritic translation in a mouse model of Down's syndrome.

Authors:  José Antonio Troca-Marín; Alexandra Alves-Sampaio; María Luz Montesinos
Journal:  J Neurosci       Date:  2011-06-29       Impact factor: 6.167

6.  Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy.

Authors:  Xiaoxing Huang; Hailong Zhang; Jun Yang; Jingfan Wu; John McMahon; Yufan Lin; Zhonglian Cao; Michael Gruenthal; Yunfei Huang
Journal:  Neurobiol Dis       Date:  2010-05-26       Impact factor: 5.996

7.  Pathogenic lysosomal depletion in Parkinson's disease.

Authors:  Benjamin Dehay; Jordi Bové; Natalia Rodríguez-Muela; Celine Perier; Ariadna Recasens; Patricia Boya; Miquel Vila
Journal:  J Neurosci       Date:  2010-09-15       Impact factor: 6.167

Review 8.  mTOR: from growth signal integration to cancer, diabetes and ageing.

Authors:  Roberto Zoncu; Alejo Efeyan; David M Sabatini
Journal:  Nat Rev Mol Cell Biol       Date:  2010-12-15       Impact factor: 94.444

9.  Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy.

Authors:  Paul S Buckmaster; Felicia H Lew
Journal:  J Neurosci       Date:  2011-02-09       Impact factor: 6.167

10.  Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.

Authors:  Ling-Hui Zeng; Nicholas R Rensing; Bo Zhang; David H Gutmann; Michael J Gambello; Michael Wong
Journal:  Hum Mol Genet       Date:  2010-11-09       Impact factor: 6.150

View more
  60 in total

1.  Activating the translational repressor 4E-BP or reducing S6K-GSK3β activity prevents accelerated axon growth induced by hyperactive mTOR in vivo.

Authors:  Xuan Gong; Longbo Zhang; Tianxiang Huang; Tiffany V Lin; Laura Miyares; John Wen; Lawrence Hsieh; Angélique Bordey
Journal:  Hum Mol Genet       Date:  2015-07-28       Impact factor: 6.150

2.  AMPD1 functional variants associated with autism in Han Chinese population.

Authors:  Lusi Zhang; Jianjun Ou; Xiaojuan Xu; Yu Peng; Hui Guo; Yongcheng Pan; Jingjing Chen; Tianyun Wang; Hao Peng; Qiong Liu; Di Tian; Qian Pan; Xiaobin Zou; Jingping Zhao; Zhengmao Hu; Kun Xia
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-08-26       Impact factor: 5.270

3.  [Chinese expert consensus on surgical treatment of tuberous sclerosis complex-related epilepsy].

Authors: 
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2019-08

4.  Spare the Neuron, Spoil the Network.

Authors:  Jamie Maguire
Journal:  Epilepsy Curr       Date:  2017 May-Jun       Impact factor: 7.500

5.  Beneficial effects of rapamycin in a Drosophila model for hereditary spastic paraplegia.

Authors:  Shiyu Xu; Michael Stern; James A McNew
Journal:  J Cell Sci       Date:  2016-12-01       Impact factor: 5.285

6.  Autophagy Modulation in Disease Therapy: Where Do We Stand?

Authors:  Michael P Nelson; John J Shacka
Journal:  Curr Pathobiol Rep       Date:  2013-12-01

Review 7.  Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases.

Authors:  Vladimir N Uversky; Vrushank Davé; Lilia M Iakoucheva; Prerna Malaney; Steven J Metallo; Ravi Ramesh Pathak; Andreas C Joerger
Journal:  Chem Rev       Date:  2014-05-15       Impact factor: 60.622

Review 8.  Ketogenic diets, mitochondria, and neurological diseases.

Authors:  Lindsey B Gano; Manisha Patel; Jong M Rho
Journal:  J Lipid Res       Date:  2014-05-20       Impact factor: 5.922

9.  mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia.

Authors:  Lena H Nguyen; Amy L Brewster; Madeline E Clark; Angelique Regnier-Golanov; C Nicole Sunnen; Vinit V Patil; Gabriella D'Arcangelo; Anne E Anderson
Journal:  Epilepsia       Date:  2015-03-06       Impact factor: 5.864

10.  Dysregulated autophagy in the RPE is associated with increased susceptibility to oxidative stress and AMD.

Authors:  Sayak K Mitter; Chunjuan Song; Xiaoping Qi; Haoyu Mao; Haripriya Rao; Debra Akin; Alfred Lewin; Maria Grant; William Dunn; Jindong Ding; Catherine Bowes Rickman; Michael Boulton
Journal:  Autophagy       Date:  2014       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.